Business
Soligenix Announces Publication Demonstrating Successful Formulation and Heat Stabilization of Filovirus Vaccine Platform for Ebola and Marburg Virus Diseases
Single-vial vaccine platform demonstrates high antibody levels against three lethal viruses PRINCETON, N.J., Aug. 23, 2021 /PRNewswire/ -- Soligenix, Inc.
About this update from Soligenix, Inc.
[{"type":"text","content":"Single-vial vaccine platform demonstrates high antibody levels against three lethal viruses\n\n\n\n PRINCETON, N.J., Aug. 23, 2021 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today a publication describing the formulation of single-vial platform presentations of monovalent (single antigen), bivalent (two antigens) and trivalent (three antigens) combinations of filovirus vaccine candidates. In collaboration with University of Hawaiʻi at Mānoa (UHM) and University of Colorado (UC) co-authors, the manuscript entitled \"Single-Vial Filovirus Glycoprotein Vaccines: Biophysical Characteristics and Immunogenicity after Co-lyophilization with Adjuvant\", has been published in Vaccine. \nThe antigens and adjuvants used in this study have been previously demonstrated to protect non-human primates (NHPs) from subsequent infection. Lyophilization of the antigens within monovalent vaccine formulations has also been demonstrated to thermostabilize the antigens at temperatures as high as 40 degrees Celsius (104 degrees Fahrenheit) for up to 12 weeks, enabling storage at ambient temperature. No currently licensed lyophilized vaccine that contains adjuvant is presented in a single-vial format and there are few reports of successfully using nano-emulsions in these lyophilized formulations. The published paper describes the use of a single-vial platform to co-lyophilize antigen(s) and a nano-emulsion adjuvant, CoVaccine HT™, maintaining key adjuvant stability characteristics including particle size and colloidal stability. Further, antibody responses previously shown for monovalent vaccines were maintained in both mice and NHPs for the trivalent single-vial co-lyophilized vaccine candidates. Most recently, one of these trivalent formulations has also been shown to protect 75% of vaccinated NHPs against subsequent Sudan ebolavirus challenge, with further development to test efficacy against other filovirus infections ongoing. \n\"Filoviruses such as Zaire ebolavirus, Sudan ebolavirus and Marburg marburgvirus are some of the most lethal viruses known, and they are endemic in areas of the world where the power supply and distribution network can be uncertain. A ...